PTSD & Trauma
rTMS Added to Cognitive Processing Therapy in Combat Veterans with PTSD
Grade A-Randomized, sham-controlled trial2018
What did this study find?
This randomized trial assigned 103 combat veterans with PTSD to active or sham repetitive TMS immediately before each weekly session of cognitive processing therapy. The active group showed significantly greater symptom reduction early in treatment, and the advantage was sustained up to six months. TMS is a clinical procedure distinct from consumer PEMF devices.
What are the details of this record?
- Full citation
- Kozel FA, Motes MA, Didehbani N, et al. Repetitive TMS to augment cognitive processing therapy in combat veterans of recent conflicts with PTSD: A randomized clinical trial. J Affect Disord. 2018;229:506-514. doi:10.1016/j.jad.2017.12.046.
- Journal
- Journal of Affective Disorders
- Authors
- Kozel FA, Motes MA, Didehbani N, DeLaRosa B, Bass C, Schraufnagel CD, Jones P, Morgan CR, Spence JS, Kraut MA, Hart J Jr
- Study design
- Randomized, sham-controlled trial
- Sample size and population
- 103 combat veterans with PTSD (54 active rTMS, 49 sham)
- Evidence grade
- Grade A- on the BioReg grading scale
- Reported findings
- Right prefrontal 1 Hz rTMS given just before weekly cognitive processing therapy produced significantly greater PTSD symptom reduction than sham plus therapy, early in treatment and sustained up to six months. Transcranial magnetic stimulation is a clinical procedure; findings do not transfer directly to PEMF devices.
- PubMed
- PMID 29351885
- Related categories
- PTSD & Trauma (category grade D to A- (TMS) / B to A- (HRV biofeedback) / F (PEMF))
A positive PEMF study is not evidence for a specific device unless the signal parameters studied, frequency, intensity, waveform, and exposure duration, are reasonably comparable to what that device produces. Where this record does not list those parameters, the source report did not publish them. See the grading methodology. Library last reviewed 2026-08-27.